Medviso Receives FDA 510(k) Approval and CE Marking for Cardiovascular Analysis Software

Medviso founder Einar Heiberg began developing image analysis algorithms as a researcher at Lund University in Sweden. Medviso was formed to meet a growing demand among clinicians for a packaged version of the algorithms. To deliver a production software application for clinical use, Medviso needed to extend and refine the algorithms, create a user interface, and deploy the algorithms as a standalone application.

To secure 510(k) clearance from the FDA for the software, the engineers needed to perform thorough regression tests on every release and generate extensive documentation.

Medviso used MATLAB to develop, test, document, and deploy its software.

Medviso engineers enhanced Heiberg’s original code with custom algorithms optimized to identify ventricular wall infarctions, flow measurements, and other heart features in the images. The images are read from files in the Digital Imaging and Communications in Medicine (DICOM) format.

Next, the engineers fine-tuned the algorithms that perform the remaining steps in the image analysis process using Image Processing Toolbox™. These algorithms first aggregate stacks of segmented images—each representing a 5–8 mm slice of the heart—to form a 3D representation of the heart. They measured changes in this 3D representation over a full cardiac cycle, using the results to calculate the maximum and minimum ventricular volume, ejection fraction, and other diagnostic measures.

The team created an interface for the image analysis algorithms that enables researchers and clinicians to view the images, verify or adjust the automated segmentation, read the computed diagnostic measures, and generate clinical reports.

To create a standalone version of the software that clinicians can use without installing MATLAB, the team packaged the algorithms and interface as a single application using MATLAB Compiler™.

In preparation for submitting the software for FDA approval, Medviso engineers wrote automated regression test scripts in MATLAB that verify each requirement of the software. They also wrote MATLAB scripts that generate documentation based on comments in the code.

Having received FDA 510(k) approval and a CE marking, the Segment CMR software is now used by clinicians in Europe and the U.S. and by more than 300 research groups worldwide.

Medviso recently released Segment CT, for analysis of cardiac computed tomography images. Developed in MATLAB, this application reuses about 75% of the code from Segment CMR.

• Development speed tripled. “Dr. Heiberg estimates that developing and evaluating quantification algorithms in MATLAB is three to four times faster than in C/C++,” says Fransson. “The language’s array operations on matrices make it easy to process stacks of images, and MATLAB is much easier to debug because we can examine the process step-by-step to resolve problems.”
• FDA submission work halved. “We release new software every two weeks, and we need to test and document each release prior to submission to the FDA,” says Fransson. “With MATLAB we cut the work in half by automating much of this process. In 20 minutes we have all the documentation and a compiled version uploaded to our website.”
• Algorithms delivered as production software. “We created the entire user interface for our software in MATLAB,” Fransson notes. “MATLAB enabled us to very quickly create an initial version, which we showed to the researchers we work with. We incorporated their feedback and improved the design before creating the production standalone version with MATLAB Compiler.”